Abortion Pill Case Heads to Supreme Court as Trump Loses Control Over Issue Ahead of Midterms

President Donald Trump had hoped to avoid abortion becoming a central issue in this year’s election. Yet, six months before the midterms, the Supreme Court is once again weighing a pivotal case involving abortion pills, as Louisiana and abortion drug manufacturers seek to expedite oral arguments in a potentially landmark dispute.

The escalating legal battle between Louisiana and the FDA over telemedicine abortion underscores the limited control Trump retains over the abortion debate, both in timing and outcome. The case has already sparked widespread confusion, uncertainty, and fear among patients, providers, and advocates across the United States.

How the Case Reached the Supreme Court

On May 1, the conservative Fifth Circuit Court of Appeals sided with Louisiana, issuing a nationwide order suspending FDA regulations that permit the abortion drug mifepristone to be prescribed via telehealth and mailed to patients. Days later, Justice Samuel Alito temporarily paused the order, extending his stay until May 14. The additional time suggests the full Supreme Court is grappling with how to proceed in a case that could reshape abortion access in America—and sooner than many court observers anticipated.

Legal Briefs Flood the Court as Stakeholders Weigh In

Last week, the Supreme Court received a flood of amicus briefs from parties with sharply conflicting interests. Former FDA officials warned of severe consequences if states were allowed to undermine drug regulations established years or decades ago. Meanwhile, doctors and reproductive health advocates cited extensive global research confirming the safety and efficacy of abortion pills, including via telemedicine.

“There’s a really long list of briefs, but nothing from the federal government. And in a case challenging the FDA’s authority, that’s remarkable.”

Conservative groups, however, repeatedly invoked the Comstock Act, a 150-year-old anti-obscenity law rarely enforced in recent decades. Named after 19th-century anti-vice crusader Anthony Comstock, the law criminalized the mailing or shipping of items intended to prevent conception or induce abortion. Reviving the Comstock Act could effectively end legal abortion access nationwide and potentially threaten other reproductive health services, such as IUDs.

Louisiana and Drug Manufacturers Push for Expedited Supreme Court Review

In its filing to the Supreme Court, Louisiana proposed an aggressive timeline: If the justices do not allow the Fifth Circuit’s suspension of mail-order mifepristone to take effect, they should fast-track the case to the 2025-2026 docket, scheduling oral arguments as soon as possible. A final decision could then be issued by late June or early July.

Drug manufacturers GenBioPro and Danco Laboratories also urged the court to consider taking the full case on an expedited schedule. The current Supreme Court term already includes highly consequential issues such as birthright citizenship and other major legal battles.